| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.
a Address correspondence to this author at: The Finsen Laboratory, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. Fax +45 31 38 54 50; e-mail p1000027{at}inet.uni-c.dk
Measurement of urokinase receptor (uPAR) in tumor extracts has prognostic value, but assay of the soluble uPAR (suPAR) in peripheral blood may offer wider applications in cancer patient management. A tumor extract uPAR ELISA was modified to eliminate nonspecific plasma protein interference, enabling specific detection of suPAR in plasma and sera with >90% recovery of added calibrator. suPAR concentrations in citrate plasma correlated with sera in 93 healthy blood donors (r = 0.84, P <0.0001), with a median value for both of 1.2 µg/L. The plasma median for 19 advanced breast cancer patients was 2.9 µg/L suPAR, and a similar increase was found for 10 advanced colon cancer patients, consistent with release of suPAR from tumors into blood. Repetitive monitoring of suPAR in cancer patients' blood may have value in assessment of prognosis and tumor recurrence.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  E. Henic, C. Borgfeldt, I. J. Christensen, B. Casslen, and G. Hoyer-Hansen Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer Clin. Cancer Res., September 15, 2008; 14(18): 5785 - 5793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lilja, A. Vickers, and P. Scardino Measurements of Proteases or Protease System Components in Blood to Enhance Prediction of Disease Risk or Outcome in Possible Cancer J. Clin. Oncol., February 1, 2007; 25(4): 347 - 348. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Piironen, A. Haese, H. Huland, T. Steuber, I. J. Christensen, N. Brunner, K. Dano, G. Hoyer-Hansen, and H. Lilja Enhanced Discrimination of Benign from Malignant Prostatic Disease by Selective Measurements of Cleaved Forms of Urokinase Receptor in Serum Clin. Chem., May 1, 2006; 52(5): 838 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Huai, A. P. Mazar, A. Kuo, G. C. Parry, D. E. Shaw, J. Callahan, Y. Li, C. Yuan, C. Bian, L. Chen, et al. Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor Science, February 3, 2006; 311(5761): 656 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Piironen, B. Laursen, J. Pass, K. List, H. Gardsvoll, M. Ploug, K. Dano, and G. Hoyer-Hansen Specific Immunoassays for Detection of Intact and Cleaved Forms of the Urokinase Receptor Clin. Chem., November 1, 2004; 50(11): 2059 - 2068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Beaufort, D. Leduc, J.-C. Rousselle, V. Magdolen, T. Luther, A. Namane, M. Chignard, and D. Pidard Proteolytic Regulation of the Urokinase Receptor/CD87 on Monocytic Cells by Neutrophil Elastase and Cathepsin G J. Immunol., January 1, 2004; 172(1): 540 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jo, K. S. Thomas, L. Wu, and S. L. Gonias Soluble Urokinase-type Plasminogen Activator Receptor Inhibits Cancer Cell Growth and Invasion by Direct Urokinase-independent Effects on Cell Signaling J. Biol. Chem., November 21, 2003; 278(47): 46692 - 46698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Memarzadeh, K. R. Kozak, L. Chang, S. Natarajan, P. Shintaku, S. T. Reddy, and R. Farias-Eisner Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer PNAS, August 6, 2002; 99(16): 10647 - 10652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Riisbro, I. J. Christensen, T. Piironen, M. Greenall, B. Larsen, R. W. Stephens, C. Han, G. Hoyer-Hansen, K. Smith, N. Brunner, et al. Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Serum and Cytosol of Tumor Tissue from Patients with Primary Breast Cancer Clin. Cancer Res., May 1, 2002; 8(5): 1132 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen, R. W. Stephens, V. Jensen, O. H. Nielsen, S. Sorensen, J. Overgaard, H. Lilja, A. Harris, et al. Total Levels of Tissue Inhibitor of Metalloproteinases 1 in Plasma Yield High Diagnostic Sensitivity and Specificity in Patients with Colon Cancer Clin. Cancer Res., January 1, 2002; 8(1): 156 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Koolwijk, N. Sidenius, E. Peters, C. F. M. Sier, R. Hanemaaijer, F. Blasi, and V. W. M. van Hinsbergh Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices Blood, May 15, 2001; 97(10): 3123 - 3131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mustjoki, N. Sidenius, C. F. M. Sier, F. Blasi, E. Elonen, R. Alitalo, and A. Vaheri Soluble Urokinase Receptor Levels Correlate with Number of Circulating Tumor Cells in Acute Myeloid Leukemia and Decrease Rapidly during Chemotherapy Cancer Res., December 1, 2000; 60(24): 7126 - 7132. [Abstract] [Full Text]
|
|
|
|
|
|
J. P. Braybrooke, K. J. O'Byrne, D. J. Propper, A. Blann, M. Saunders, N. Dobbs, C. Han, J. Woodhull, K. Mitchell, J. Crew, et al. A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis Clin. Cancer Res., December 1, 2000; 6(12): 4697 - 4704. [Abstract] [Full Text]
|
|
|
|
|
|
L. S. Gutierrez, A. Schulman, T. Brito-Robinson, F. Noria, V. A. Ploplis, and F. J. Castellino Tumor Development Is Retarded in Mice Lacking the Gene for Urokinase-Type Plasminogen Activator or Its Inhibitor, Plasminogen Activator Inhibitor-1 Cancer Res., October 1, 2000; 60(20): 5839 - 5847. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. E. P. Dekkers, T. ten Hove, A. A. te Velde, S. J. H. van Deventer, and T. van der Poll Upregulation of Monocyte Urokinase Plasminogen Activator Receptor during Human Endotoxemia Infect. Immun., April 1, 2000; 68(4): 2156 - 2160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Foekens, H. A. Peters, M. P. Look, H. Portengen, M. Schmitt, M. D. Kramer, N. Brunner, F. Janicke, M. E. M.-v. Gelder, S. C. Henzen-Logmans, et al. The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients Cancer Res., February 1, 2000; 60(3): 636 - 643. [Abstract] [Full Text]
|
|
|
|
|
|
A. N. Pedersen, N. Brunner, G. Hoyer-Hansen, P. Hamer, D. Jarosz, B. Larsen, H. J. Nielsen, and R. W. Stephens Determination of the Complex between Urokinase and Its Type-1 Inhibitor in Plasma from Healthy Donors and Breast Cancer Patients Clin. Chem., August 1, 1999; 45(8): 1206 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Stephens, H. J. Nielsen, I. J. Christensen, O. Thorlacius-Ussing, S. Sorensen, K. Dano, and N. Brunner Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis J Natl Cancer Inst, May 19, 1999; 91(10): 869 - 874. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
